Willox J C, McAllister E J, Sangster G, Kaye S B
Br J Cancer. 1986 Jul;54(1):19-23. doi: 10.1038/bjc.1986.147.
The concentration of magnesium in serum has been shown to fall to potentially dangerously low levels after several courses of treatment with cis-diamminedichloroplatinum II (cis-platin). The aims of this study were to examine the effects of magnesium supplementation on predicted outcome of treatment, rate of response to treatment and toxicity of treatment. Sixteen patients with testicular cancer were studied in detail over a 14 month period. One patient with an ovarian dysgerminoma was also included in the study. Eight patients were randomised to receive magnesium supplements both intravenous and oral; nine did not. The non-supplemented group showed significantly greater renal tubular damage as assessed by urine N-acetyl-B-D-glucosaminidase (NAG). There was a trend towards a reduction in treatment delays due to neutropenic episodes in the supplemented group, and serum magnesium concentrations remained significantly higher. Neither group showed differences in tumour growth rates or outcome. These results show that magnesium supplements are of considerable benefit and show no harmful effects in patients receiving cis-platin treatment. It is is suggested that magnesium supplements should be a routine part of the treatment regime, and that these should comprise both i.v. supplements during treatment and oral supplements between courses.
血清镁浓度在接受几个疗程的顺式二氨二氯铂（顺铂）治疗后已显示会降至潜在危险的低水平。本研究的目的是检验补充镁对治疗预期结果、治疗反应率及治疗毒性的影响。在14个月期间对16例睾丸癌患者进行了详细研究。一名卵巢无性细胞瘤患者也被纳入研究。8例患者被随机分配接受静脉和口服镁补充剂；9例未接受。通过尿N-乙酰-β-D-氨基葡萄糖苷酶（NAG）评估，未补充组显示出明显更严重的肾小管损伤。补充组因中性粒细胞减少发作导致的治疗延迟有减少趋势，且血清镁浓度仍显著更高。两组在肿瘤生长率或结果方面均未显示出差异。这些结果表明，镁补充剂对接受顺铂治疗的患者有相当大的益处且无有害影响。建议镁补充剂应成为治疗方案的常规组成部分，且应包括治疗期间的静脉补充剂和疗程之间的口服补充剂。
